BioPharma Dive

BioPharma Dive
Share

BioPharma Dive

 •  September 4

Dive Brief: Jazz Pharmaceuticals plc has inked a new deal allowing it to potentially co-develop and co-commercialize three antibody-drug conjugate (ADC) programs from ImmunoGen Inc. Per deal terms, Jazz is handing over $75 million upfront plus as much as $100 million in research funding that would span over seven years. For any program Jazz opts...

BioPharma Dive

 •  August 23

What issues do patients cite as barriers to clinical study participation? How far are they willing to travel to participate in a study and how much more willing are they to participate knowing that their physician is aware of the study? We asked these questions – and more – to a group of 135,000 people who opted in to the LabCorp database to...

BioPharma Dive

 •  July 17

This feature is part of a series focused on Alzheimer's disease. To view other posts in the series, check out the spotlight page. Alzheimer’s disease is one of the top ten leading causes of death in the U.S., affecting more and more Americans as the country’s population ages. But of the leading causes of death, it's the only one that lacks an...

BioPharma Dive

 •  June 1

Dive Brief: Japanese drugmaker Eisai Co., Ltd. announced Tuesday an agreement with Charles River Laboratories to extend the two companies' existing drug discovery partnership for a third year. Launched in February 2016, the collaboration is aimed at developing new treatments for tropical and neurological diseases, particularly novel anti-malaria...

BioPharma Dive

 •  May 15

In the summer of 2015, two new cholesterol-lowering medicines launched to high expectations, demonstrating impressive efficacy in high-risk patients. The drugs, Repatha (evolocumab) from Amgen and Praluent (alirocumab) from Sanofi and Regeneron, were the first in a class of treatments known as PCSK9 inhibitors. Both promised to be potent new...

BioPharma Dive

 •  May 15

Dive Brief: European antitrust regulators are investigating Aspen Pharma, a generic drugmaker based in Durban, South Africa, for allegedly abusing its "dominant market position" and sharply increasing the prices of five off-patent chemotherapy drugs. The scrutiny of Aspen's pricing practices marks the first time the European Commission has formally...

BioPharma Dive

 •  May 10

Dive Brief: Amid an effort to revamp the drug industry's image, PhRMA rolled out new membership criteria Tuesday aimed at blunting criticism the trade association had expanded to include companies that spent little on research and development. Members will now be required to invest an average of $200 million per year and at least 10% of global...

BioPharma Dive

 •  April 10

Most of the world’s highest-priced drugs are for rare diseases. In the U.S., those are conditions that affect about a couple hundred thousand people. But some affect as few as a couple hundred people worldwide. Surprising? Turns out that even small patient populations can now deliver a healthy profit. Price tags for such drugs can reach more than...

BioPharma Dive

 •  March 16

Dive Brief: Japanese drugmaker Takeda has teamed up with an investment firm and a drug distributor to collectively invest ¥10 billion ($88 million) in a new joint venture aimed at fast track drug discovery in the renal, metabolic and cardiovascular therapeutic spaces. Dubbed Scohia Pharma, the venture will be based out of Takeda's Shonan research...